A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Sep 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Jun 2017 Planned initiation date changed from 19 Jun 2017 to 14 Aug 2017.
- 01 Jun 2017 Planned End Date changed from 20 May 2020 to 20 Apr 2020.